Intra-Cellular Therapies Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
| Date | Value | Name | Entity | Role | Shares | Max Price |
|---|---|---|---|---|---|---|
| 06 Nov 23 | SellUS$860,417 | Mark Neumann | Individual | 15,639 | US$55.02 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
| Owner Type | Number of Shares | Ownership Percentage |
|---|---|---|
| Private Companies | 19,628 | 0.0199% |
| Individual Insiders | 2,194,207 | 2.23% |
| Institutions | 96,280,892 | 97.8% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Top Shareholders
| Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
|---|---|---|---|---|---|---|
| 11,452,357 | US$888.6m | 4.36% | 0.06% | |||
| 9,094,302 | US$705.7m | 6.49% | 0.01% | |||
| 8,193,544 | US$635.8m | 9.03% | 0.01% | |||
| 4,743,770 | US$368.1m | 0% | 100.0% | |||
| 3,627,308 | US$281.5m | -4.62% | 1.11% | |||
| 3,066,400 | US$237.9m | -3.28% | 2.77% | |||
| 2,255,555 | US$175.0m | 0% | 2.6% | |||
| 2,220,850 | US$172.3m | 4% | 0.01% | |||
| 2,001,791 | US$155.3m | 4.75% | 0.01% | |||
| 2,000,000 | US$155.2m | -23.1% | 5.36% | |||
| 1,918,430 | US$148.9m | -2.91% | 0.02% | |||
| 1,818,046 | US$141.1m | 0.62% | 0.04% | |||
| 1,802,027 | US$139.8m | -4.85% | 0.05% | |||
| 1,767,184 | US$137.1m | -0.56% | 0.05% | |||
| 1,763,475 | US$136.8m | -2.89% | 0.02% | |||
| 1,628,244 | US$126.3m | -3.77% | 1.17% | |||
| 1,564,153 | US$121.4m | 14.4% | 0.14% | |||
| 1,553,135 | US$120.5m | 10.7% | 0.1% | |||
| 1,334,743 | US$103.6m | -23.6% | 0.07% | |||
| 1,261,857 | US$97.9m | -11.9% | 0.38% | |||
| 1,260,897 | US$97.8m | 92% | 0.01% | |||
| 1,197,203 | US$92.9m | 14.9% | 0.01% | |||
| 1,165,948 | US$90.5m | -14.9% | 3.99% | |||
| 1,050,309 | US$81.5m | 0% | no data | |||
| 1,039,821 | US$80.7m | 33.5% | 0.01% |